Keros Therapeutics, Inc. (KROS) Net margin 2019–2025
Keros Therapeutics, Inc. (KROS) net profit margin by fiscal year — reported net income divided by reported revenue.
35.7%FY2025 · since FY2019: -123.4% → 35.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 35.7% | +5313.2 pp |
| FY2024 | -5277.5% | +96041.7 pp |
| FY2023 | -101319.2% | — |
| FY2021 | -292.3% | — |
| FY2019 | -123.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice